news2023-03-09T13:10:55+01:00

news

TAmiRNA shares microRNA biomarker insights at FIDELIO training webinar

TAmiRNA is a key partner in the EU-funded Innovative Training Network FIDELIO, which aims to train the next generation of scientists in tackling the challenges of bone fragility in diabetic patients. The  webinar "MicroRNAs: small RNAs with big potential as biomarkers and drug targets in bone diseases" is a one-hour session hosted by TAmiRNA founder and CEO Dr. Matthias Hackl. He show how [...]

Circulating miRNAs in bone health and disease

We want to draw your attention to our latest review which appeared in the special issue on miRNAs in Bone Research in Bone. In this review, we summarize important molecular basics of microRNA function and release and provide recommendations for best (pre-)analytical practices and documentation standards for circulating microRNA research required for generating high quality data and ensuring reproducibility of results. We review [...]

microRNA-146a controls age-related bone loss

We want to draw your attention to the latest publication in cooperation with TAmiRNA. The study identifies a novel and unexpected role of miR‐146a in bone homeostasis. miR‐146a increases with age and acts as an epigenetic molecular switch terminating bone accrual, leading to bone loss during aging by downregulating bone anabolic Wnt signaling. Conversely, loss of miR‐146a leads to continuous bone accrual during [...]

MedUni Wien “Researcher of the Month” Oktober 2020

We want to congratulate Dr. Patrick Starlinger to his award “Researcher of the Month” for his work in cooperation with TAmiRNA GmbH, in Hepatology. "Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures." Hepatology. 2019 Jun;69(6):2636-2651. Click here for more information on TAmiRNA services Click here to read the story

By |October 6th, 2020|Categories: biomarker, Liver disease, microRNAs, Personalized medicine|Tags: , , , , |Comments Off on MedUni Wien “Researcher of the Month” Oktober 2020

Dr. Michael Nodine´s Spike-in technology is nominated for a Houska prize

The “Houska“ Prize, awarded annually by the B&C Foundation, is Austria´s biggest private award for applied research. Dr. Michael Nodine, Gregor Mendel Institute of Molecular Plant Biology (GMI), was nominated for his work on the development of methods for nucleic acid quantification. A major issue they encountered was the lack of absolute quantification of small RNA levels, making the comparison between tissues difficult. To [...]

By |October 1st, 2020|Categories: biomarker, microRNA, microRNA services, Personalized medicine, safety, test service|Tags: , , , , , |Comments Off on Dr. Michael Nodine´s Spike-in technology is nominated for a Houska prize

TAmiRNA bietet validierte Coronavirus Antikörpertests und SARS-CoV-2 PCR-Analysen an

By |July 29th, 2020|Categories: Coronavirus, CoV-2, PCR testing service, SARS, SARS-CoV-2 Antibody Test|Tags: , , , |Comments Off on TAmiRNA bietet validierte Coronavirus Antikörpertests und SARS-CoV-2 PCR-Analysen an

microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring

We want to draw your attention to the latest review of TAmiRNA and the King's College London, in Cardiovascular Diabetology. "microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring." Krammer TL, Mayr M & Hackl M. Int. J. Mol. Sci. 2020, 21(10), 3477; doi.org/10.3390/ijms21103477 In this review, we explain the secretion of miRNAs upon platelet activation and discuss the potential use [...]

By |May 29th, 2020|Categories: biomarker, biomarkers, microRNA, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR|Tags: , , , , , |Comments Off on microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring

TAmiRNAs SARS CoV-2 offers

TAmiRNA now offers a test service for direct detection of SARS-CoV-2 viral RNA in biological samples. Moreover we offer a validated SARS-CoV-2 Antibody Test (Lateral Flow Method). Click here for more Information

By |May 24th, 2020|Categories: Coronavirus, CoV-2, liquid biopsies, Personalized medicine, SARS, test service, viral RNA|Tags: , , |Comments Off on TAmiRNAs SARS CoV-2 offers

TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA

The sequencing advance allows genome scale analysis of miRNAs and promises a more efficient discovery approach for safety biomarkers, enabling retrospective analysis. Dr. Kseniya Khamina, TAmiRNA research scientist, will deliver a presentation on ‘Next-generation sequencing pipeline for genome-scale analysis of circulating microRNAs as discovery approach for safety biomarkers’ (P338) during the Biomarkers Poster Session on Day Two, CC Exhibit Hall, of the meeting. [...]

By |February 24th, 2020|Categories: biomarker, biomarkers, drug development, drug discovery, liquid biopsies, LMD, microRNAs, Personalized medicine|Tags: , , , , , , , , |Comments Off on TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA

New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response

We want to draw your attention to the latest publication of the King's College London, in Cardiovascular Diabetology. The research team provides new evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response in type-2 diabetics with cardiovascular disease. "Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels." Parker WAE, Schulte C, Bawari T, et al. Cardiovasc Diabetol. 2020 Jan 7;19(1):3. doi: 10.1186/s12933-019-0981-3. click here to [...]

By |January 13th, 2020|Categories: biomarker, biomarkers, clopidogrel, diabetes, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR, type 2 diabetes mellitus|Tags: , , , , , , , , , |Comments Off on New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response
Go to Top